The Greater Boston Diabetes Cluster

(Page 2 of 3)

consists of an insulin-carrying device that adheres to the skin under a patient’s shirt; patients control insulin delivery with a handheld device.

Bedford, MA

MicroCHIPS is working on what could be a breakthrough in managing diabetes, a tiny implant that can monitor blood sugar continuously and alert patients when levels fall outside of set limits. The glucose sensor uses reservoir-array technology developed at MIT by CEO John Santini and company co-founders and MIT professors Michael Cima and Bob Langer.


Cambridge, MA

CombinatoRx (NASDAQ:CRXX) has several drugs in its pipeline based on its platform that combines different drug molecules to form new treatments for different ailments. Indeed, the company’s drug for Type 2 diabetes, now in mid-stage clinical trials, is a combination of an anti-cholesterol drug and a painkilling molecule.

Elixir Pharmaceuticals
Cambridge, MA

Elixir is in the late stages of developing a combination drug for Type 2 diabetes. The startup’s lead diabetes drug, which is a combination of metformin and mitiglinide, is intended to provide both reduce blood sugar levels and provide boosts in insulin production after meals. We wrote more about the latest clinical trial of the drug, which Elixir plans to market under the name Metgluna, late last year.

Cambridge, MA

It’s early days for Escoublac, a startup housed in big biotech Biogen Idec’s incubator near its headquarters in Cambridge, but its research could lead to new drugs for diabetes. Escoublac has licensed technology based of the discovery of … Next Page »

Single Page Currently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.

3 responses to “The Greater Boston Diabetes Cluster”

  1. Don’t forget that the Joslin Diabetes Research Center–one of top in the world–is here as well.

  2. You missed Covidien from Mansfield.
    They are working hard on educating people about the resolution of type 2 diabetes through gastric bypass surgery.

  3. Scott says:

    You did not include Biodel, Inc., which is based in Danbury, Connecticut. At present, BIOD has a rapid-acting version of biosynthetic human insulin pending FDA approval they are calling Linjeta(TM) which is not an insulin analogue, but removes zinc from the insulin molecule using ethylenediaminetetraacetic acid (usually abbreviated as “EDTA”) which destabilizes the hexamer of the insulin molecule; then, by adding citric acid, which masks the surface charges and further destabilizes the insulin molecule so that it does not form hexamers as it would normally when injected into the skin without these modifications.

    Although it was not approved in October 2010 as many had anticipated, the company’s business plan always presumed the product would not be sold until 2011 anyway. Beyond that, BIOD has several interesting items beyond Linjeta in its pipeline including an adjustable basal insulin analogue, and a stable form of the counterregulatory hormone glucagon, as well as a sublingual form of insulin that can be taken orally.